ImmunityBio, Inc. (IBRX)
UndervaluedFundamental
46
Price
$9.44
Market Cap
$10.00B
Part 1 · What the company is worth
Overview
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$166M
Trailing 12 months (through 6/30/2026)
Net Income
$-992M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$-309M
Total Equity
$-500M
Total Liabilities
$1.00B
Current Ratio
5.72
Interest Coverage
4.21
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$12.75
Current Price
$9.44
Margin of Safety
+26.0%
Fair Value Range
$12.11 - $13.39
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
70.2%
P/B Ratio
-
P/FCF
-
Gross Margin
99.3%
ROIC
-36.0%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-36.0%
WACC
7.6%
ROIC − WACC
-43.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (9)
- EPS shows upward trend
- Gross Margin 99.3%
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 184.3%
- Analyst Consensus 90% Buy
- Net Margin Trend -598.6% vs -648.6%
- Piotroski F-Score 5/9
Failed (9)
- Price CAGR 4.20%
- ROIC -36.1%
- Operating Margin -151.9%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -193.3%
- Earnings Surprise avg -19.4%
- Share Dilution 38.6%
Unavailable (9)
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.S., M.Sc. | Founder, Executive Chairman and Global Chief Scientific & Medical Officer | 72 |
| Mr. Richard Gerald Adcock | President, CEO & Director | 56 |
| Mr. David C. Sachs | Chief Financial Officer | 47 |
| Ms. Regan J. Lauer | Chief Accounting Officer | 55 |
| Dr. Barry J. Simon M.D. | Chief Corporate Affairs Officer & Director | 60 |
| Dr. Enrique Diloné Ph.D., RAC | Chief Technology Officer | 58 |
| Ms. Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy | - |
| Ms. Emily Arison | Senior Vice President of Human Resources | - |
| Dr. Leonard S. Sender M.D. | Chief Medical Officer of Liquid Tumors & Cell Therapy | - |
| Dr. Sandeep K. Reddy M.D. | Chief Medical Officer | - |
Audit Risk
6
Board Risk
8
Compensation Risk
9
Shareholder Rights Risk
6
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-23
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-04
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-08-04
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for IBRX, sourced from Markets Gazette.
- 2/25/2026POSITIVEImmunityBio Supersedes Expectations With Fivefold Revenue Increase
ImmunityBio Inc. has significantly exceeded analyst expectations, driving a surge in its stock price due to exceptional financial results. Sales of its drug Anktiva demonstrated an impressive 750% increase, contributing to an overall fivefold revenue growth that comfortably beat estimates. This substantial revenue beat, coupled with a new strategic partnership in Saudi Arabia, fuels the company's future growth prospects. Investors should closely monitor the long-term impact of these sales figures and the partnership on ImmunityBio's trajectory within the biopharmaceutical sector.
- 2/23/2026POSITIVEStock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700%
ImmunityBio captured the market's attention on February 23, 2026, with its stock surging on extraordinary news: revenue from its flagship drug, Anktiva, jumped by a staggering 700%. This phenomenal figure overshadowed the company's current, albeit deep, operating losses. Investors are clearly betting on the long-term potential of the drug and the company's ambitious global expansion strategy. While the losses remain a factor to watch, the revenue growth trajectory suggests strong market adoption and a promising future. The market's reaction indicates that top-line growth is currently the most powerful catalyst for the stock's valuation, outweighing concerns about short-term profitability.
via Markets Gazette